News > Article details

Boan Biotech Completes Phase 3 Trial of Its PD-1 Inhibitor BA1104 (Nivolumab) in China, with Primary Endpoint Met

2026.11.17 | Boan Biotech,Shandong Boan Biotech, Boan Innovative Antibodies,Boan Biosimilar

Yantai, China, November 17, 2026 — Boan Biotech announced today that the Phase 3 clinical trial in China of its PD-1 inhibitor BA1104 (nivolumab injection) has been completed and has met its primary endpoint. The company will shortly submit a marketing authorization application for the product to China’s National Medical Products Administration (NMPA). BA1104 is the first biosimilar to Opdivo® to have completed a Phase 3 clinical trial in China. Based on China’s Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars, the company intends to seek approval for indications currently approved for Opdivo in China.

Nivolumab is a fully human monoclonal antibody of the IgG4 subtype targeting the programmed death-1 (PD-1) receptor. It blocks PD-1 from binding to its ligands PD-L1 and PD-L2, enhancing T-cell-mediated antitumor responses. Nivolumab is a cornerstone of cancer immunotherapy. Publicly available information shows that Opdivo has been approved for multiple indications across a range of tumor types in dozens of countries and regions worldwide. Its clinical use extends across treatment settings, including neoadjuvant therapy before surgery, adjuvant therapy after surgery, and first-line and later-line treatment of advanced cancer. Treatment regimens include monotherapy, combinations with chemotherapy, and combinations with novel immune checkpoint inhibitors. In 2025, global sales of Opdivo reached US$10.049 billion, an increase of 8% year over year.1 

BA1104 is being developed in accordance with relevant guidelines for biosimilar development in China, the United States, Europe, and Japan. The Phase 3 clinical trial was a randomized, double-blind, multicenter study designed to compare the efficacy and safety of BA1104 and Opdivo, each in combination with chemotherapy, in patients with advanced or metastatic esophageal squamous cell carcinoma.

The Phase 3 clinical study met its prespecified primary endpoint. The results showed that the confidence interval for the objective response rate (ORR) ratio between BA1104 and the reference product fell entirely within the prespecified equivalence margins, demonstrating equivalence between the two treatments. The independent central imaging review results showed good agreement with investigator assessments. Results for secondary efficacy endpoints, including disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), were highly similar between the two groups, with no clinically meaningful differences in efficacy observed. BA1104 demonstrated a favorable overall safety and tolerability profile, and the two products had highly similar safety profiles. Positivity rates for anti-drug antibodies (ADA) and neutralizing antibodies (NAb) were low and comparable between the two groups, indicating similar immunogenicity.

Boan Biotech previously completed comparative analytical and nonclinical studies of BA1104 and Opdivo, and conducted a randomized, double-blind, single-dose Phase 1 clinical study in healthy Chinese male volunteers to evaluate the pharmacokinetic (PK) profiles, safety, and immunogenicity of the two products. The 90% confidence intervals for the geometric mean ratios of AUC0–∞, AUC0–t, and Cmax all fell within the prespecified range of 80.00%–125.00%, confirming that their PK profiles were highly similar. The study results have been published in the international journal BioDrugs2.  In the Phase 1 clinical study, ADA and NAb positivity rates were comparable between the two products, indicating similar immunogenicity.

Boan Biotech is also advancing the development of BA1104 outside China. The company previously held a Biosimilar Biological Product Development (BPD) Type 2b meeting with the U.S. Food and Drug Administration (FDA). The FDA agreed to a “streamlined” clinical development strategy under which a single PK similarity study (a Phase 1 trial) would be sufficient to support submission of a Biologics License Application (BLA) in the United States, without the need for a Phase 3 clinical trial. In addition, the company plans to pursue registration and marketing authorization for BA1104 in more countries and regions.

PD-1 inhibitors are a cornerstone of current cancer immunotherapy. In addition to its BA1104 biosimilar development program, Boan Biotech is actively exploring the therapeutic potential of combining BA1104 with the company’s proprietary novel antibodies. Through its “immuno-oncology + antibody-drug conjugates (IO + ADC)” development strategy, the company is building a differentiated pipeline of innovative therapies and exploring new approaches that balance efficacy and safety while addressing drug resistance more effectively, with the aim of achieving new breakthroughs in cancer treatment.

 

References:
1. Bristol Myers Squibb. Key facts: product revenue. https://www.bms.com/investors/financial-reporting/key-facts.html.
2. Wang W, Zhang S, Dou C, Hu B, Song H, Qi F, Zhao Y, Li X, Zhou M, Xie J, Deng K, Wu Q, Ye L, Cui C, Liu L, Huang J, Yang G. Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects. BioDrugs. 2024 Nov;38(6):855-865. doi: 10.1007/s40259-024-00679-w. Epub 2024 Sep 24. PMID: 39317850.

 

More Next

Contact us

No.39 Keji Avenue, Hi-Tech Industrial Development Zone, Yantai, Shandong, China

(86)0535-4379111

Follow me